

Pergamon

 Tetrahedron Letters, Vol. 37, No. 22, pp. 3785-3788, 1996

 Copyright © 1996 Elsevier Science Ltd

 Printed in Great Britain. All rights reserved

 -7
 0040-4039/96 \$15.00 + 0.00

PII: S0040-4039(96)00713-7

## Synthesis of E-Selectin Inhibitors: Use of an Aryl-Cyclohexyl Ether as a Disaccharide Scaffold

Aijun Liu,\* Kathleen Dillon, Robert M. Campbell, Don C. Cox and Donna M. Huryn

Roche Research Center, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110

Abstract: A series of potential E-selectin antagonists were designed and synthesized based on the bound conformation of sLe<sup>x</sup>, as well as the functional group requirements for anti-adhesion activity. A non-carbohydrate scaffolding using an aryl-cyclohexyl ether which can orient the critical acid and fucose residues in appropriate positions has been investigated. The inhibitory activity of members of this series suggests the feasibility of non-carbohydrate E-selectin antagonists. Copyright © 1996 Elsevier Science Ltd

E-Selectin-mediated cell adhesion via the protein's interaction with carbohydrates on the surface of cells is an early event in the recruitment of leukocytes to sites of inflammation. Evidence also exists that E-selectin may play a role in the interaction of tumor cells with the endothelium of blood vessels, thereby mediating mechanisms of tumor metastasis.<sup>1</sup> Sialyl Lewis X (sLe<sup>x</sup>) appears to be the minimal carbohydrate determinant expressed on the surface of neutrophils which interacts with E-selectin, and the isolated tetrasaccharide can act as an antagonist to prevent E-selectin-mediated adhesion (IC<sub>50</sub> ~ 1mM).<sup>2</sup> Inhibition of E-Selectin by use of sLe<sup>x</sup> analogs may therefore present opportunities for new therapeutic agents for inflammatory diseases and for the prevention of metastasis of certain types of tumors.



Previous studies on sLe<sup>x</sup> and its analogs suggest that the acid moiety of the sialic acid and the fucose group play an essential role in binding to E-selectin, as their removal or modification completely abolishes inhibitory activity.<sup>3</sup> Modifications at the glucosamine and galactose groups are quite well tolerated, and this observation forms the basis of the hypothesis that these two carbohydrates act mainly as a scaffold which maintains the acid and fucose groups in an appropriate orientation for binding.<sup>4</sup> We have set out to design and synthesize a series of  $sLe^x$  mimetics<sup>5</sup> in which a non-carbohydrate moiety replaces the internal galactose-glucosamine unit, while the critical acid and fucose groups are maintained.

The galactose-glucosamine unit has been replaced with an aryl-cyclohexyl ether as shown in compounds 1 - 4. This new scaffold allows the fucose and acid groups to adopt an orientation similar to that observed in



the conformation of sLe<sup>x</sup> bound to E-selectin.<sup>6</sup> While the conformation of the fucose unit would be expected to be quite flexible, we envisioned that in highly polar media such as water, the more hydrophobic  $\alpha$ -surface of the fucose ring would prefer to stay near the aromatic ring due to hydrophobic collapse<sup>7</sup> in water. This preorganization could orient the critical acid and the fucose groups in a conformation appropriate for binding to Eselectin. Interactions of an aromatic ring with a face of a pyranose ring has been previously observed in x-ray structures of protein-carbohydrate complexes.<sup>8</sup> An NMR study of the compound **4** in D<sub>2</sub>O revealed an NOE effect between the two aromatic rings and the methyl function of the fucose. It has been reported that introduction of a hydrophobic substituent such as a methyl or a phenyl to the methylene position of a carboxyl methyl group, which serves as a viable replacement for the sialic acid in sLe<sup>x</sup>, would increase the binding affinity.<sup>9</sup> This fact, coupled with the possibility of increasing hydrophobic environment of the aromatic center, led to the attachment of a benzyl group to the phenolic oxygen.

Synthesis of the aryl-cyclohexyl ether mimetic is illustrated in **Scheme 1**. 2,4-Dihydroxybenzaldehyde was selectively protected at the meta-position with a *t*-butydimethyl silyl group under mild conditions to generate **5**. Under more strongly basic conditions, with a mixture of DMSO and toluene as a solvent, the *ortho*-hydroxyl group was protected as its benzyl ether. Elaboration of the aldehyde function via a Horner-Emmons reaction allowed introduction of an acid precursor, and at the same time, removed the TBDMS protecting group to provide **6**, which was suitable for further coupling.

The phenolic intermediate 6 was heated together with an excess of cyclohexene oxide under basic conditions to afford 7 as a racemic mixture. Coupling of the phenol 7 with the fucosyl bromide derivative<sup>10</sup> 8 yielded a mixture of diastereomers 9 and 10, which were easily separable by flash chromatography. Hydrogenation using Pd(C) as a catalyst removed all benzyl protecting groups, and reduced the double bond at the same time. The acids 1 and 3 were prepared by direct basic hydrolysis of the hydrogenated intermediates 11 and 12. To synthesize the benzyl substituted analogs 2 and 4, the phenolic hydoxyl groups of the hydrogenated intermediates 11 and 12 were re-attached with a benzyl group selectively with a mild condition, and the resultant compounds 13 and 14 were then hydrolyzed under the basic condition. X-ray structures of the two intermediates 11 and 12 were obtained to determine the absolute stereo chemical orientation of the substituents in the final products.<sup>11</sup>





<sup>a</sup> Conditions: (a) TBDMSCl, imidazole, CH<sub>2</sub>Cl<sub>2</sub>, RT, 88%; (b) NaH, BnBr, toluene and DMSO, 0 °C - RT, 90%; (c) 5 was added to a solution of (EtO)<sub>2</sub>P(O)CH<sub>2</sub>CO<sub>2</sub>Et and KH in DMF, RT, 80%; (d) excess epoxide, K<sub>2</sub>CO<sub>3</sub>, DMF, 95 °C, 90%; (e) (i) 8, Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (ii) 7, Et<sub>4</sub>NBr, ground sieves (4 Å), DMF, the solution made in (i), RT, 9 (44%) and 10 (38%) were separated by flash chromatography; (f) H<sub>2</sub> (1 atm), Pd (C), EtOAc, RT, 92% for both; (g) Cs<sub>2</sub>CO<sub>3</sub>, BnBr, 18-Crown-6, DMF, RT, 82% for both; (h) 0.5 N aq. NaOH, 1,4-dioxane, RT, purified by reverse phase flash chromatography, 42% - 59% for 1 - 4.

All four compounds<sup>12</sup> were tested in a competitive cell-free ELISA assay that measures inhibition of soluble E-selectin binding to sLe<sup>x</sup>-polyacryamides.<sup>4c</sup> Compound 4 showed activity equivalent to sLe<sup>x</sup> with an IC<sub>50</sub> = 0.87 mM, while its diastereomer 2 exhibited less potent activity (IC<sub>50</sub> ~ 3.3 mM). The compounds 1 and 3 did not exhibit any inhibitory activity under these assay conditions.

The activity displayed by 2 and 4 further strengthens the hypothesis of the role of the galactoseglucosamine in interactions of sLe<sup>x</sup> with E-selectin. To date, carbohydrate-based antagonists of E-selectin binding appear to exhibit potencies similar to those of sLe<sup>x</sup> itself (IC  $_{50} \sim 1$ mM).<sup>4c, 13</sup> The potencies observed for the compounds described, containing only one carbohydrate unit, suggest that non-carbohydrate antagonists of E-selectin (carbohydrate-mimetics) are a feasible alternative to sugar-based analogs.

Acknowledgment: We are grateful to Drs. S. Tam, S. DeBernardo and K.-C. Luk for their earlier work in the synthesis of the compound 8 as well as its coupling to sugar moieties, and to Mr. G. J. Sasso for the NOE study of the compound 4.

## **References and Notes**

- (a) Springer, T. A. Nature, 1990, 346, 425-434.
   (b) Lasky, L. A. Science, 1992, 258, 964-969.
   (c) Walz, G.; Aruffo, A.; Kolanus, W.; Bevilacqua, M.; Seed, B. Science, 1990, 250, 1132-1135.
- (a) Phillips, M. L.; Nudelman, E.; Gaeta, F. C. A.; Perez, M.; Singhal, A. K.; Hakomori, S.; Paulson, J. C. Science, 1990, 250, 1130-1132.
   (b) Berg, E. L.; Robinson, M. K.; Mansson, O.; Butcher, E. C.; Magnan, J. L. J. Biol. Chem. 1991, 266, 14869-14872.
   (c) Tiemeyer, M.; Swiedler, S. J.; Ishihara, M.; Moreland, M.; Schweingruber, H.; Hirtzer, P.; Brandley, B. K. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 1138-1142.
   (d) Tyrrell, D.; James, P.; Rao, N.; Foxall, C.; Abbas, S.; Dasgupta, F.; Nashad, M.; Hasegawa, A.; Kiso, M.; Asa, D.; Kidd, J.; Brandley, B. K. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 10372-10376.
- (a) Yuen, C. T.; Lawson, A. M.; Chai, W.; Larkin, M.; Stoll, M. S.; Stuart, A. C.; Sullivan, F. X.; Ahern, T. J.; Freizi, T. Biochemistry, 1992, 31, 9126-9131.
   (b) Larkin, M.; Ahern, T. J.; Shaffer, M.; Sako, D.; O'Brien, J.; Yuen, C.-T.; Lawson, A. M.; Childs, R. A.; Barone, K. M.; Langer-Safer, P. R.; Hasegawa, A.; Kiso, M.; Larsen, G. R.; Feizi, T. J. Bio. Chem. 1992, 267, 13661-13668.
- (a) Nelson, R. M.; Dolich, S.; Aruffo, A.; Cecconi, O.; Bevilacqua, M. P. J. Clin. Invest. 1993, 91, 1157-1166 (b) Stahl, W.; Sprengard, U.; Kretzschmar, G.; Kunz, H. Angew. Chem. Int. Ed. Engl. 1994, 33, 2096-2098 (c) Campbell, R. M.; Cox, D.; Gaizband, D.; Schwinge, V.; DeBernado, S.; Holman, M.; Richou, A.; Sluboski, B.; Tam, S.; Wolitzky, B.; Huryn, D. Inflammation Research Association Meeting, Sept. 25-29, 1994, Mountain Laurel Resort, PA.
- Cox, D.; Gaizband, D.; Schwinge, V.; DeBernado, S.; Holman, M.; Richou, A.; Sluboski, B.; Tam, S.; Wolitzky, B.; Huryn, D. Inflammation Research Association Meeting, Sept. 25-29, 1994, Mountain Laurel Resort, PA.
  (a) Huang, H; Wong, C.-H. J. Org. Chem. 1995, 60, 3100-3106. (b) Kogan, T. P.; Dupré, B.; Keller, K. M.; Scott, I. L.;; Bui, H.; Market, R. V.; Beck, P. J.; Voytus, J. A.; Revelle, B. M.; Scott, D. J. Med. Chem. 1995, 38, 4976-4984. (c) Uchiyama, T.; Vassilev, V. P.; Kajimoto, T.; Wong, W.; Huang, H.; Lin, C. -C.; Wong, C. -H. J. Am. Chem Soc. 1995, 117, 5395-5396. (d) Toepfer, A.; Kretzschmar, G.; Bartnik, E. Teirahedron Lett. 1995, 36, 9161-9164. (e) Kaila, N.; Yu, H. -A. Xiang, Y. Tetrahedron Lett. 1995, 36, 5503-5506. (f) Ragan, J. A.; Cooper, K. Bioorg. Med. Chem. Lett. 1994, 4, 2563-2566. (g) Allanson, N. M.; Davidson, A. H.; Martin, F. M. Tetrahedron Lett. 1993, 34, 3945-3948.
- (a) Fry, D. C.; Cook, C. M.; Huryn, D. M.; Tam, S. Y.; Huann, F. M. Fernbaron Lett. 1995, 54, 5945-5946.
   (a) Fry, D. C.; Cook, C. M.; Huryn, D. M.; Tam, S. Y.; Huang, K.-S.; Burns, D. K. Unpublished results. (b) Kogan, T. P; Revelle, B. M.; Tapp, S.; Scott, D.; Beck, P. J. J. Biol. Chem. 1995, 270, 14047-14055. (c) Cooke, R. M.; Hale, R. S.; Lister, S. G.; Shah, G.; Weir, M. P. Biochemistry, 1994, 33, 10591-10596. (d) Lin, Y. C.; Hummel, C. W.; Huang, D-H.; Ichikawa, Y.; Nicolaou, K. C.; Wong, C-H. J. Am. Chem. Soc. 1992, 114, 5452-5454. (e) Ball, G. E.; O'Neill, R. A.; Shultz, J. E.; Lowe, J. B.; Weston, B. W.; Nagy, J. O.; Brown, E. G.; Hobbs, C. J.; Berdnaski, M. D. J. Am. Chem. Soc. 1992, 114, 5449-5451.
- 7. Dasgupa, F.; Musser, J. H.; Nemattala, A.; Nashed, M. A. Division of Carbohydrate Chemistry, 205th ACS National Meeting, Denver, Co. 1993.
- 8. See reviews (a) Vyas, N. K. Current Opinion in Structural Biology, 1991, 1, 732-740. (b) Quiocho, F. A. Pure & Appl. Chem. 1989, 61, 1293-1306.
- 9. (a) Wiley, R. A.; Rich, D. H. Med. Res. Rev. 1993, 13, 327-384. (b) Rich, D. H. in Perspectives in Medicinal Chemistry, Testa, B.; Kyburg, E.; Fuhre, W.; Gigger, W. Eds.; VCH: New York, 1993.
- Compound 8 was prepared via adaptation of the procedures in this paper: Yamazaki, F.; Sato, S.; Nukada, T.; Ito, Y.; Ogawa, T. Carbohydrate Research, 1990, 201, 31-50.
- 11. Luk, K.-C.; Jack, B.; Todaro, L. J.; Chiu, A.-M. Unpublished results.
- All spectral data for new compounds are in accordance with the assigned structure. The data for the four final products are:
   1: <sup>1</sup>H NMR (200 MHz, D<sub>2</sub>O), δ 1.10 (d, 3H, J=6.4Hz), 1.28-1.50 (m, 4H,), 1.76 (d, 2H, J=10.6Hz), 2.14 (d, 2H, J=13.4Hz), 2.50 (t, 2H, J=7.3Hz), 2.82 (t, 2H, J=7.4Hz), 3.43-3.48 (m, 2H), 3.63-3.71 (m, 2H), 3.82-3.83 (m, 1H), 4.32 (m, 1H), 5.01 (d, 1H, J=3.8Hz), 6.84 (s, 2H), 6.90 (s, 1H); HRMS (Fab) obs'd for C<sub>21</sub>H<sub>29</sub> O<sub>9</sub>Na+H, 449.1780; calc'd, 449.1788.

**2:** <sup>1</sup>H NMR (200 MHz, D<sub>2</sub>O),  $\delta$  1.04 (d, 3H, J=6.5 Hz), 1.20-1.50 (m, 4H), 1.70-1.80 (m, 2H), 2.10-2.20 (m, 2H), 2.42 (t, 2H, J=8.0Hz), 2.86 (t, 2H, J=8.0Hz), 3.38 (m, 2H), 3.55-3.77 (m, 3H), 4.30-4.40 (m, 1H), 4.98 (d, 1H, J=3.4Hz), 5.14 (s, 2H), 6.82-7.00 (m, 3H), 7.38-7.50 (m, 5H); HRMS (Fab) obs'd for C<sub>28</sub>H<sub>35</sub>O<sub>9</sub>Na+H, 539.2254; calc'd, 539.2257.

3: <sup>1</sup>H NMR (200 MHz,  $D_2O$ ),  $\delta$  1.16 (d, 3H, J=6.4Hz), 1.32 (m, 3H), 1.50 (m, 1H), 1.71 (m, 2H), 2.10 (m, 2H), 2.49 (t, 2H, J=7.2Hz), 2.82 (t, 2H, J=7.3Hz), 3.63-3.84 (m, 4H), 4.10-4.25 (m, 2H), 5.18 (d, 1H, J=2.3Hz), 6.83 (s, 2H), 6.93 (s, 1H); HRMS (Fab) obs'd for C<sub>21</sub>H<sub>29</sub>O<sub>9</sub>Na+H, 449.1790; calc'd, 449.1788

**4**: <sup>1</sup>H NMR (200 MHz, D<sub>2</sub>O),  $\delta$  1.14 (d, 3H, J=6.4Hz), 1.32 (m, 3H), 1.52 (m, 1H), 1.71 (m, 2H), 2.20 (m, 2H), 2.42 (t, 2H, J=7.6Hz), 2.86 (t, 2H, J=8.0Hz), 3.64-3.82 (m, 4H), 4.10-4.18 (m, 1H), 4.19-4.28 (m, 1H), 5.17 (s, 2H), 5.18 (d, 1H, J=3.5Hz), 6.87-7.06 (m, 3H), 7.38-7.53 (m, 5H); HRMS (Fab) obsd for C<sub>28</sub>H<sub>35</sub>O<sub>3</sub>Na+H, 539,2233; calcd, 539,2257. Defense  $\delta$  A. Conte C. A. Lin X. C. Labitanz X: Wrap C. H. Any Chen Son 1003, 115 (520).

13. Defrees, S. A.; Gaeta, C. A.; Lin, Y.-C.; Ichikawa, Y.; Wong, C.-H. J. Am. Chem. Soc. 1993, 115, 7549-7550.

(Received in USA 23 February 1996; revised 21 March 1996; accepted 2 April 1996)